# First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

> **NCT07216066** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 46 (estimated)

## Conditions studied

- Parkinsons Disease

## Interventions

- **DRUG:** ALN-SNCA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07216066
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2029-06-07
- **Final completion:** 2029-06-07
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216066, "First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07216066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*